PeptideJournal
Guides17 min read

Best Peptides for Hormonal Balance in Women

Women's hormones don't just fluctuate during menopause. They shift through monthly cycles, pregnancy, postpartum, perimenopause, and beyond.

Women's hormones don't just fluctuate during menopause. They shift through monthly cycles, pregnancy, postpartum, perimenopause, and beyond. At every stage, the balance between estrogen, progesterone, testosterone, growth hormone, thyroid hormones, and cortisol determines how you feel, sleep, think, and look.

When that balance breaks, the consequences show up everywhere. Fatigue that coffee can't fix. Weight that won't budge. Sleep disruption. Low libido. Brain fog. Thinning hair and skin that suddenly looks older.

Standard hormone replacement therapy (HRT) works well for many women, but it doesn't address every dimension of hormonal health. Peptide therapy is a complementary approach -- not replacing HRT, but filling gaps that hormones alone can't reach.

Here is what the research says about the most relevant peptides for women's hormonal health.

Table of Contents

How Women's Hormonal Balance Works (and Breaks Down)

Your hormonal system runs on a hierarchy. The hypothalamus releases GnRH in pulses, which tells the pituitary to release FSH and LH, which tell the ovaries to produce estrogen, progesterone, and testosterone. The hypothalamus also controls growth hormone (via GHRH), thyroid function (via TRH), and stress hormones (via CRH).

Every one of these hormones influences the others. Low estrogen reduces growth hormone secretion. High cortisol suppresses thyroid function. Poor gut health impairs estrogen metabolism. It's a web, not a ladder.

Women's growth hormone levels peak in the late teens and decline roughly 14% per decade [1]. By perimenopause (typically ages 40-50), you're dealing with a double hit: declining sex hormones and already-reduced growth hormone. Add stress-driven cortisol elevation and metabolic slowdown, and you get the constellation of symptoms that so many women in their 40s and 50s experience.

Peptides can intervene at multiple points in this web. The key is matching the right peptide to your specific hormonal gap.

Kisspeptin: The Master Switch of Reproductive Hormones

Kisspeptin is a neuropeptide that sits at the very top of the reproductive hormone cascade. Produced by neurons in the hypothalamus, kisspeptin is the primary activator of GnRH release. Without kisspeptin signaling, GnRH doesn't pulse, and the entire downstream hormone chain -- LH, FSH, estrogen, progesterone -- stalls [2].

This peptide is getting serious scientific attention for women's health. Here's why.

Menopause and hot flashes. The decline in estrogen during menopause removes a feedback signal that normally keeps kisspeptin neurons in check. The result: kisspeptin neurons become hyperactive and fire erratically, which disrupts the hypothalamic thermoregulatory center. This is one mechanism behind hot flashes [3]. Neurokinin B (NKB) receptor antagonists -- drugs that target the same KNDy neurons as kisspeptin -- are already approved for treating menopausal vasomotor symptoms (fezolinetant/Veozah). The science connecting kisspeptin biology to menopausal symptoms is strong.

Fertility. Kisspeptin-54 infusion has been shown to trigger LH pulses in women, including during IVF protocols. A 2022 review in Reproductive Biology and Endocrinology documented kisspeptin's role in stimulating oocyte maturation for assisted reproduction, with potentially fewer risks of ovarian hyperstimulation compared to standard hCG triggers [4].

Diagnostic tool. Kisspeptin challenges can help diagnose hypothalamic amenorrhea (absent periods due to hypothalamic dysfunction from stress, low body weight, or excessive exercise). If kisspeptin administration triggers an LH response, the pituitary and ovaries are functional -- the problem is at the hypothalamic level [5].

Practical note: Kisspeptin is primarily used in clinical research settings for IVF and diagnostic purposes. It's not widely available as a general peptide therapy. However, research into longer-acting kisspeptin analogs (like MVT-602) is ongoing [3].

Research status: Strong human data from clinical trials and IVF studies. A 2025 comprehensive review in Physiological Reviews detailed kisspeptin's role in reproductive health across the lifespan [6].

CJC-1295 + Ipamorelin: Growth Hormone for Metabolism and Body Composition

The combination of CJC-1295 (a GHRH analog) and Ipamorelin (a selective growth hormone secretagogue) is probably the most commonly used peptide protocol in women's health clinics. It addresses the growth hormone decline that accelerates during perimenopause and menopause.

Why this matters for women specifically: Women's GH levels are influenced by estrogen. Before menopause, higher estrogen actually stimulates GH secretion. When estrogen drops, GH drops further. The combined decline contributes to increased visceral fat, reduced lean mass, thinner skin, poor sleep quality, and slower recovery from exercise [7].

CJC-1295 extends the duration of GH-releasing pulses. A single injection increased mean GH concentrations 2- to 10-fold for up to 6 days and IGF-1 levels 1.5- to 3-fold for 9-11 days [8]. Ipamorelin adds selectivity: it stimulates GH release without significantly affecting cortisol or prolactin, which matters for women already dealing with stress-related hormonal disruption [9].

What women typically report:

  • Better sleep quality (GH is released primarily during deep sleep)
  • Reduced abdominal fat
  • Improved skin elasticity and thickness
  • More energy and faster recovery from workouts
  • Better mood and mental clarity

GH genuinely influences all of these systems. The question is whether peptide-stimulated GH release is sufficient to produce clinically meaningful changes.

Important caveat: GH-stimulating peptides can worsen insulin resistance in some individuals. Women with PCOS or prediabetes should be monitored. GH therapy is not appropriate during active cancer treatment.

Research status: CJC-1295 has human pharmacokinetic data. Ipamorelin has Phase II clinical trial data. The combination is widely used clinically but lacks large-scale randomized controlled trials specific to women's hormonal health.

PT-141 (Bremelanotide): Sexual Health and Desire

PT-141 (bremelanotide, brand name Vyleesi) is the only peptide on this list with full FDA approval for a women's health indication. It's approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women [10].

Unlike sildenafil (Viagra) or tadalafil, which increase blood flow to genitals, PT-141 works in the brain. It activates melanocortin-4 receptors (MC4R) in the hypothalamus, which are involved in sexual arousal and desire pathways. It's a fundamentally different approach: it targets the "wanting," not just the "mechanics."

Clinical trial data: In the RECONNECT Phase 3 trials, premenopausal women with HSDD who used bremelanotide showed statistically significant improvements in sexual desire and reductions in distress related to low desire compared to placebo [10]. About 25% of treated women had a clinically meaningful response, compared to about 17% on placebo.

Those numbers don't sound huge, but HSDD is complex. The fact that a single-mechanism peptide produces measurable benefit in a quarter of patients is meaningful.

What PT-141 doesn't do: It doesn't change hormone levels. For women whose low desire is driven by hormone deficiency (common in menopause), addressing the underlying deficit may matter more.

Side effects: Nausea (about 40% of users). Given as a subcutaneous injection at least 45 minutes before anticipated sexual activity, no more than once daily or 8 times monthly.

Research status: FDA-approved. Phase 3 data available. Approved for premenopausal women, though off-label postmenopausal use occurs.

BPC-157: Gut Health and Hormonal Downstream Effects

BPC-157 (Body Protection Compound-157) doesn't directly alter hormone levels. But the gut-hormone connection is so important that BPC-157 earns a place on this list through its gut-healing properties.

The estrobolome connection. Your gut microbiome contains a collection of bacteria called the estrobolome that metabolizes estrogen. When gut dysbiosis occurs, the estrobolome becomes dysfunctional. This can lead to either excessive estrogen recirculation (estrogen dominance) or inadequate estrogen levels -- both of which cause symptoms [11].

Gut inflammation and cortisol. Chronic gut inflammation elevates cortisol. Elevated cortisol suppresses GnRH pulsatility, reduces progesterone production, and shifts the estrogen-progesterone ratio. For many women, fixing the gut is the prerequisite to fixing hormonal balance.

BPC-157 has been shown to stabilize intestinal permeability, protect against NSAID-induced gut damage, and support gut-brain axis function in animal studies [12, 13]. While no human clinical trials exist for BPC-157, the gut-healing mechanism is well-documented in preclinical research, and the gut-hormone connection is well-established in human endocrinology.

Practical note: BPC-157 is often used alongside probiotics and dietary changes. Women with IBS, food sensitivities, bloating, or a history of antibiotic/NSAID use may be good candidates for a gut-first approach. See Best Peptides for Women Over 40.

Research status: Extensive animal data. No human clinical trials. The gut-hormone connection is well-supported by human research, making the rationale reasonable even without peptide-specific human data.

GHK-Cu: Skin, Hair, and Collagen Support

GHK-Cu is a copper-binding tripeptide that naturally occurs in your blood, saliva, and urine. Its levels decline significantly with age -- plasma GHK-Cu concentrations drop from about 200 ng/mL at age 20 to 80 ng/mL by age 60 [14].

For women dealing with hormonal skin changes, GHK-Cu is one of the most relevant peptides available.

Collagen and elastin. Estrogen decline during menopause causes a roughly 30% loss of skin collagen in the first five years [15]. GHK-Cu stimulates collagen synthesis, increases elastin production, and promotes glycosaminoglycan synthesis (which keeps skin hydrated). A 2020 review in Aging Pathobiology and Therapeutics confirmed GHK-Cu's ability to stimulate collagen production in both in vitro and in vivo studies [14].

Wound healing and skin repair. GHK-Cu accelerates wound healing and tissue remodeling. A 2024 study in BioImpacts reviewed the evidence for topical GHK as an anti-wrinkle peptide and confirmed beneficial effects on skin thickness, firmness, and wrinkle reduction [16].

Hair. GHK-Cu increases hair follicle size and stimulates growth. The evidence is smaller than for skin, but the mechanism is consistent with the peptide's tissue-repair properties.

Anti-inflammatory effects. GHK-Cu suppresses inflammatory markers that increase with estrogen decline, including IL-6 and TNF-alpha. This matters because post-menopausal inflammation ("inflammaging") contributes to skin aging, joint pain, and cardiovascular risk.

How it's used: Available as a topical serum (for skin) and as a subcutaneous injection (systemic). Many women use topical GHK-Cu alongside injectable protocols. See Best Peptides for Skin Anti-Aging.

Research status: In vitro and animal data for collagen stimulation and wound healing. Limited but positive human data for topical anti-aging. Widely used clinically.

Semaglutide: Weight Management During Hormonal Transitions

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist that has transformed weight management. For women going through hormonal transitions, weight gain is often the most visible and frustrating symptom -- and one that resists diet and exercise because the hormonal environment has changed.

Why menopause makes weight loss harder. Declining estrogen shifts fat storage from hips and thighs (subcutaneous) to the abdomen (visceral). Reduced GH lowers metabolic rate. Increased cortisol promotes fat storage. Insulin sensitivity drops. The result: caloric restriction that worked in your 30s stops working in your 40s and 50s.

Semaglutide works through multiple mechanisms: it slows gastric emptying, reduces appetite, and may directly improve insulin sensitivity. In clinical trials, weekly semaglutide 2.4 mg produced 12-15% body weight loss over 68 weeks [17]. Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist, has shown even greater weight loss in trials.

Hormonal interaction considerations:

  • Weight loss can improve hormonal balance by reducing estrogen from fat tissue (relevant for estrogen-dominant conditions)
  • Rapid weight loss may temporarily worsen hormonal symptoms as stored estrogen is released
  • Thyroid medication doses may need adjustment as weight changes
  • Bone density monitoring matters -- significant weight loss can accelerate bone loss postmenopause
  • Muscle mass preservation requires adequate protein and resistance training. See Best Peptides for Fat Loss for more.

Practical note: Semaglutide is a prescription medication requiring physician monitoring. The FDA requires a thyroid C-cell tumor warning, though human evidence suggests this rodent-specific risk doesn't translate to people [18].

Research status: Extensive Phase 3 data. FDA-approved for type 2 diabetes and weight management. Not specifically studied for menopause-related weight gain, but the metabolic mechanisms are highly relevant.

Thymosin Alpha-1: Immune Modulation for Autoimmune Conditions

Thymosin Alpha-1 (Ta1) is a 28-amino-acid thymic peptide that modulates immune function. It's relevant for women because autoimmune diseases disproportionately affect women -- roughly 80% of autoimmune disease patients are female [19].

Hashimoto's thyroiditis affects women 7-10 times more often than men. Rheumatoid arthritis, lupus, and Sjogren's syndrome also preferentially affect women. The common thread: immune dysregulation driven partly by estrogen's immunomodulatory effects.

Ta1 promotes dendritic cell maturation, T-cell function, and regulatory T cells (Tregs) that prevent autoimmune attack [20]. For women with autoimmune thyroid disease or premature ovarian insufficiency with autoimmune features, Ta1 addresses the immune imbalance rather than masking symptoms.

Research status: Approved in over 30 countries for hepatitis B and as an immune adjuvant. Clinical use for autoimmune conditions is growing. A 2024 safety and efficacy review confirmed it as "well-tolerated and effective" across multiple conditions [21].

Oxytocin: The Connection Peptide

Oxytocin is a nine-amino-acid peptide hormone produced by the hypothalamus. Often simplified as the "love hormone," its effects on women's health go well beyond social bonding.

Stress and cortisol. Oxytocin inhibits the HPA axis, directly reducing cortisol output. For women whose hormonal imbalance is stress-driven (and the resulting cortisol-progesterone competition for synthesis pathways), oxytocin can help restore balance from the top down.

Mood and bone health. Oxytocin has anxiolytic effects independent of sex hormone levels. Emerging research also shows it may promote bone formation and inhibit bone resorption -- especially relevant postmenopause, when estrogen withdrawal accelerates bone loss.

Sexual function. Oxytocin levels rise during arousal and peak during orgasm. Intranasal oxytocin has been studied (with mixed results) for improving sexual satisfaction in women. It's available as a prescription nasal spray or sublingual formulation through compounding pharmacies.

Research status: Well-established endogenous hormone. Studied in numerous human trials for stress, mood, and social behavior. Bone health research is still early.

Gonadorelin: Supporting the HPG Axis

Gonadorelin is synthetic GnRH -- the same hormone your hypothalamus produces to drive the entire reproductive hormone cascade. When given in a pulsatile fashion (mimicking natural GnRH release), it can restart ovarian function in women with hypothalamic amenorrhea.

Clinical use: Pulsatile GnRH administration has been used since the 1980s to restore menstrual cycles and fertility in women with hypothalamic amenorrhea (absent periods due to stress, low body weight, or functional hypothalamic suppression). It works by restoring the natural pulsatile signal that the hypothalamus has stopped sending [22].

For perimenopause and beyond: Gonadorelin is less relevant in natural menopause (ovarian follicle depletion, not hypothalamic suppression). But for younger women with premature ovarian insufficiency or functional suppression (stress-related, exercise-induced), it can be a targeted intervention. See our Kisspeptin profile for more.

Research status: FDA-approved as a diagnostic agent. Decades of clinical use for pulsatile GnRH therapy. Well-established mechanism and safety profile.

Peptide Comparison Table for Women

PeptidePrimary Benefit for WomenHormones AffectedBest Age RangeEvidence Level
KisspeptinReproductive hormone regulationLH, FSH, estrogen, progesterone20s-40s (fertility); all ages (research)Strong human clinical data
CJC-1295 + IpamorelinGH optimization, body compositionGH, IGF-135+Human PK data; clinical use
PT-141Sexual desireBrain melanocortin pathwaysPremenopausal (FDA); all ages (off-label)FDA-approved (Phase 3 trials)
BPC-157Gut health, downstream hormonal supportIndirect (via gut-hormone axis)All agesAnimal studies
GHK-CuSkin, hair, collagenIndirect (tissue repair)35+In vitro/animal; limited human
SemaglutideWeight managementGLP-1 pathway, insulin35+FDA-approved (Phase 3 trials)
Thymosin Alpha-1Immune balance, autoimmune supportIndirect (immune modulation)All agesApproved in 30+ countries
OxytocinStress, mood, bonding, bone healthCortisol (reduces), oxytocinAll agesStrong human data
GonadorelinRestore menstrual cyclesLH, FSH, estrogen, progesteroneReproductive ageFDA-approved; decades of use

Age-Specific Considerations

Women in Their 20s-30s

Hormonal issues at this stage are often functional -- driven by stress, underfueling (under-eating for activity level), PCOS, or hypothalamic suppression. Relevant peptides include:

  • Kisspeptin or Gonadorelin for hypothalamic amenorrhea or fertility challenges
  • BPC-157 if gut dysfunction is contributing to hormonal imbalance
  • PT-141 for HSDD (FDA-approved for premenopausal women)

Women in Their 40s (Perimenopause)

This is when hormonal decline becomes tangible. Estrogen and progesterone fluctuate wildly. GH continues its decline. Sleep deteriorates. Consider:

  • CJC-1295 + Ipamorelin for GH optimization (energy, sleep, body composition)
  • BPC-157 for gut health support during a metabolically stressful transition
  • GHK-Cu as skin and collagen changes accelerate
  • Semaglutide if perimenopausal weight gain is resistant to diet and exercise

For more age-specific guidance, see Best Peptides for Women Over 40.

Women 50+ (Postmenopause)

Ovarian hormone production has largely ceased. The focus shifts to managing consequences and optimizing remaining hormonal axes:

  • CJC-1295 + Ipamorelin (GH decline accelerates after menopause)
  • Semaglutide or Tirzepatide for metabolic support
  • GHK-Cu for skin and tissue integrity
  • Oxytocin for stress management and bone health support
  • Thymosin Alpha-1 if autoimmune conditions are present
  • See also our guide on Best Peptides for Anti-Aging & Longevity for longevity-focused protocols

What About Peptides and Fertility?

Kisspeptin is the most studied peptide for fertility, with human data showing it can trigger oocyte maturation during IVF with a lower risk of ovarian hyperstimulation syndrome compared to standard hCG triggers [4]. Gonadorelin (pulsatile GnRH) has been used for decades to restore ovulatory cycles in women with hypothalamic amenorrhea.

Peptides to avoid during pregnancy or fertility treatment:

  • Semaglutide -- contraindicated in pregnancy. Discontinue at least 2 months before planned conception.
  • GH-stimulating peptides -- insufficient safety data in pregnancy.
  • PT-141 -- not studied in pregnant women.

Always discuss peptide use with your reproductive endocrinologist if you're trying to conceive.

Frequently Asked Questions

Can peptides replace hormone replacement therapy (HRT)?

No. HRT directly replaces hormones your body no longer produces. Peptides stimulate your body's own production, support gut health, improve immune function, or target specific symptoms like low sexual desire. Many women use both. Certain peptides (CJC-1295/Ipamorelin for GH, kisspeptin for reproductive hormones) can partially compensate, but they don't replicate what estrogen does for bone, heart, and brain health.

What peptide should I start with for general hormonal support?

It depends on your primary complaint. For body composition and energy: CJC-1295 + Ipamorelin. For gut-related hormonal issues: BPC-157. For skin aging: GHK-Cu. For low libido: PT-141. For weight management: Semaglutide. A physician experienced in peptide therapy can help prioritize based on your labs and symptoms. Our Peptide Stacking Guide covers how to combine peptides safely.

Are peptides safe for long-term use in women?

Safety varies. Semaglutide and PT-141 have FDA approval with large trial data. Thymosin Alpha-1 is approved in 30+ countries. CJC-1295/Ipamorelin are widely used but lack long-term women-specific studies. BPC-157 has extensive animal safety data but no human trials. General principle: work with a physician, monitor labs, adjust based on response.

I'm 45 and gaining weight around my midsection despite no diet changes. Which peptides might help?

Classic perimenopausal pattern: declining estrogen shifts fat to the abdomen, declining GH reduces lean mass, and insulin sensitivity drops. Address the foundation first -- HRT discussion, resistance training, adequate protein, sleep. For peptide support, CJC-1295 + Ipamorelin can help with body composition, and semaglutide or tirzepatide can address appetite and metabolic resistance. See Best Peptides for Fat Loss for a deeper dive.

Do peptides interact with birth control?

Most peptides here don't interfere with hormonal birth control. Kisspeptin and gonadorelin stimulate the reproductive axis and could theoretically interact. PT-141 works on brain pathways, not sex hormones. Semaglutide may reduce absorption of oral medications (including oral contraceptives) due to slowed gastric emptying -- discuss this with your prescriber. GH peptides and BPC-157 are not known to affect contraceptive efficacy.

Are there peptides specifically for PCOS?

PCOS involves insulin resistance, androgen excess, and disrupted GnRH pulsatility. Semaglutide can help with insulin resistance and weight. Selank may help with stress. Kisspeptin research in PCOS is active but not yet clinical. No peptide directly reduces androgens. The most impactful interventions for PCOS remain weight management, insulin sensitization, and stress reduction -- peptides can support all three, but they're not standalone treatments.

The Bottom Line

Women's hormonal health involves dozens of interconnected signaling molecules, not just estrogen and progesterone. Peptide therapy offers tools that work at different points in this network -- from the hypothalamus (kisspeptin, gonadorelin) to the gut (BPC-157), immune system (Thymosin Alpha-1), growth hormone axis (CJC-1295/Ipamorelin), metabolic pathways (semaglutide), desire (PT-141), stress response (oxytocin), and tissue repair (GHK-Cu).

None of these is a magic bullet. The women who benefit most are the ones who first address the basics: sleep, exercise, nutrition, stress management, and where indicated, conventional HRT. Peptides fill specific gaps that these foundations leave behind.

The science is strongest for kisspeptin, PT-141 (FDA-approved), semaglutide (FDA-approved), and gonadorelin (decades of use). CJC-1295/Ipamorelin and GHK-Cu have strong rationale and widespread clinical use but need more women-specific trials. BPC-157 remains the most promising peptide without human clinical data.

Work with a physician who understands both hormones and peptides. Get comprehensive labs. Build from the foundation up.

References

  1. Ho KY, et al. "Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations." Journal of Clinical Endocrinology & Metabolism. 1987;64(1):51-58.

  2. Prashar V, et al. "Hypothalamic kisspeptin neurons: integral elements of the GnRH system." Reproductive Sciences. 2023;30(3):802-822. https://doi.org/10.1007/s43032-022-01027-5

  3. Meczekalski B, et al. "A new hope for women with vasomotor symptoms: neurokinin B antagonists." Journal of Clinical Medicine. 2025;14(5):1438. https://doi.org/10.3390/jcm14051438

  4. Hu KL, et al. "Advances in clinical applications of kisspeptin-GnRH pathway in female reproduction." Reproductive Biology and Endocrinology. 2022;20:81. https://doi.org/10.1186/s12958-022-00953-y

  5. Anderson RA, Millar RP. "The roles of kisspeptin and neurokinin B in GnRH pulse generation in humans, and their potential clinical application." Journal of Neuroendocrinology. 2022;34(5):e13081. https://doi.org/10.1111/jne.13081

  6. Koysombat K, et al. "Kisspeptin and neurokinin B: roles in reproductive health." Physiological Reviews. 2025. https://doi.org/10.1152/physrev.00015.2024

  7. Holt RIG, Ho KKY. "The use and abuse of growth hormone in sports." Endocrine Reviews. 2019;40(4):1163-1185. https://doi.org/10.1210/er.2018-00265

  8. Teichman SL, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.

  9. Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.

  10. Kingsberg SA, et al. "Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials." Obstetrics & Gynecology. 2019;134(5):899-908. https://doi.org/10.1097/AOG.0000000000003500

  11. Baker JM, et al. "Estrogen-gut microbiome axis: physiological and clinical implications." Maturitas. 2017;103:45-53.

  12. Park JM, Lee HJ, Sikiric P. "BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection." Current Pharmaceutical Design. 2020;26(25):2971-2981. https://doi.org/10.2174/1381612826666200523180301

  13. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 may recover brain-gut axis and gut-brain axis function." Pharmaceuticals. 2023;16(5):676. https://doi.org/10.3390/ph16050676

  14. Dou Y, et al. "The potential of GHK as an anti-aging peptide." Aging Pathobiology and Therapeutics. 2020;2(1):58-61. https://pmc.ncbi.nlm.nih.gov/articles/PMC8789089/

  15. Brincat M, et al. "Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy." Obstetrics & Gynecology. 1987;70(1):123-127.

  16. Mortazavi SM, et al. "Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective." BioImpacts. 2024;14(3):30133. https://pmc.ncbi.nlm.nih.gov/articles/PMC11830136/

  17. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine. 2021;384(11):989-1002.

  18. Hu W, et al. "Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials." Frontiers in Endocrinology. 2022;13:927859. https://doi.org/10.3389/fendo.2022.927859

  19. Angum F, et al. "The prevalence of autoimmune disorders in women: a narrative review." Cureus. 2020;12(5):e8094.

  20. Wei Y, et al. "Thymosin alpha-1 in cancer therapy: Immunoregulation and potential applications." International Immunopharmacology. 2023;118:110090. https://doi.org/10.1016/j.intimp.2023.110090

  21. Dinetz E, Lee E. "Comprehensive review of the safety and efficacy of thymosin alpha 1 in human clinical trials." Alternative Therapies in Health and Medicine. 2024. https://www.alternative-therapies.com/oa/pdf/Dinetz.pdf

  22. Crowley WF, et al. "The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women." Recent Progress in Hormone Research. 1985;41:473-531.